Stay updated with breaking news from Christophe Bourdon. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pfizer picks from Roche's executive team, snagging pharma early R&D leader William Pao as the Big Pharma's next chief development officer. Leo Pharma poaches from ... a Danish meme stock for its new CEO, who will lead a reorganization of the dermatology biopharma. And Sio Gene Therapies CEO Cheruvu is out the door as Parkinson's program also hits the exit.
Orphazyme A/SCompany announcement No. 24/2021Inside informationCompany Registration No. 32266355 Progress made in understanding potential...
Enfin ! Enfin les "enfants de choeur" ont repris le chemin des salles pour l'enregistrement du rendez-vous culte sur...
– June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced a restructuring intended to enable the company to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C (NPC). The resulting cost savings include an approximate two thirds reduction in our global workforce. Orphazyme remains committed to pursuing regulatory approval in Europe and assessing a path forward for arimoclomol in the U.S. following receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) on June 17, 20...
Press release content from Globe Newswire. The AP news staff was not involved in its creation. Orphazyme announces restructuring to focus resources on supporting a path forward for ... ORPHAZYME A/SJune 28, 2021 GMT Orphazyme A/S - Copenhagen – June 28, 2021 – Orphazyme A/S (ORPHA.CO; ORPH), a late-stage biopharmaceutical company, today announced a restructuring intended to enable the company to advance its corporate strategy and the development of arimoclomol for Niemann-Pick disease type C (NPC). The resulting cost savings include an approximate two thirds reduction in our global workf...